Search Tag: semaglutide

2024 27 Nov

A comprehensive meta-analysis published in The Lancet Diabetes & Endocrinology highlights the significant kidney and cardiovascular benefits of glucagon-like peptide-1 (GLP-1) receptor agonists for individuals with and without diabetes. This landmark study, the largest of its kind, underscores the potential of these medications to transform care...Read more

2024 24 Jul

  Semaglutide emerged as the most frequently prescribed GLP-1 receptor agonist (GLP-1RA) in 2023 by a significant margin. A nationwide study revealed a substantial rise in new GLP-1RA prescriptions over the past decade, especially since 2020.    While semaglutide dominated prescriptions in 2023, the study also noted a shift in the patient...Read more

2023 05 Sep

Novo Nordisk, the Danish pharmaceutical giant behind the weight-loss medication Wegovy (active ingredient - semaglutide), has become Europe's most valuable company, dethroning the French luxury conglomerate LVMH.   Following the successful launch of Wegovy in the U.K., the company's shares saw a significant uptick in value. As trading closed...Read more